115 related articles for article (PubMed ID: 30805584)
1. S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma.
Marín-Rubio JL; Pérez-Gómez E; Fernández-Piqueras J; Villa-Morales M
Carcinogenesis; 2019 Oct; 40(10):1260-1268. PubMed ID: 30805584
[TBL] [Abstract][Full Text] [Related]
2. Deregulated FADD expression and phosphorylation in T-cell lymphoblastic lymphoma.
Marín-Rubio JL; de Arriba MC; Cobos-Fernández MA; González-Sánchez L; Ors I; Sastre I; Fernández-Piqueras J; Villa-Morales M
Oncotarget; 2016 Sep; 7(38):61485-61499. PubMed ID: 27556297
[TBL] [Abstract][Full Text] [Related]
3. Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer.
Bhojani MS; Chen G; Ross BD; Beer DG; Rehemtulla A
Cell Cycle; 2005 Nov; 4(11):1478-81. PubMed ID: 16258269
[TBL] [Abstract][Full Text] [Related]
4. A Dual Role for FADD in Human Precursor T-Cell Neoplasms.
Marín-Rubio JL; Vela-Martín L; Gudgeon J; Pérez-Gómez E; Sidgwick FR; Trost M; Cunningham DL; Santos J; Fernández-Piqueras J; Villa-Morales M
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499482
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the Fas-apoptosis-signalling pathway by functional polymorphisms at Fas, FasL and Fadd and their implication in T-cell lymphoblastic lymphoma susceptibility.
Villa-Morales M; González-Gugel E; Shahbazi MN; Santos J; Fernández-Piqueras J
Carcinogenesis; 2010 Dec; 31(12):2165-71. PubMed ID: 20889682
[TBL] [Abstract][Full Text] [Related]
6. Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin lymphomas.
Drakos E; Leventaki V; Atsaves V; Schlette EJ; Lin P; Vega F; Miranda RN; Claret FX; Medeiros LJ; Rassidakis GZ
Hum Pathol; 2011 Aug; 42(8):1117-24. PubMed ID: 21315423
[TBL] [Abstract][Full Text] [Related]
7. FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer.
Cimino Y; Costes A; Damotte D; Validire P; Mistou S; Cagnard N; Alifano M; Régnard JF; Chiocchia G; Sautès-Fridman C; Tourneur L
Br J Cancer; 2012 Jun; 106(12):1989-96. PubMed ID: 22669160
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid synthase-associated protein with death domain: a prognostic factor for survival in patients with nasopharyngeal carcinoma.
Li J; Wen Q; Xu L; Wang W; Luo J; Chu S; Xie G; Shi L; Huang D; Li J; Fan S
Hum Pathol; 2014 Dec; 45(12):2447-52. PubMed ID: 25305096
[TBL] [Abstract][Full Text] [Related]
9. PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.
Garcia EG; Veloso A; Oliveira ML; Allen JR; Loontiens S; Brunson D; Do D; Yan C; Morris R; Iyer S; Garcia SP; Iftimia N; Van Loocke W; Matthijssens F; McCarthy K; Barata JT; Speleman F; Taghon T; Gutierrez A; Van Vlierberghe P; Haas W; Blackburn JS; Langenau DM
Leukemia; 2021 Mar; 35(3):679-690. PubMed ID: 32606318
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated FADD is not prognostic for local control in T1-T2 supraglottic laryngeal carcinoma treated with radiotherapy.
Wachters JE; Schrijvers ML; Slagter-Menkema L; Mastik M; Langendijk JA; de Bock GH; Roodenburg JL; van der Laan BFAM; van der Wal JE; Schuuring E
Laryngoscope; 2017 Sep; 127(9):E301-E307. PubMed ID: 28304089
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of miRNA-17 and miRNA-19 is associated with unfavorable prognosis in patients with T-cell lymphoblastic lymphoma.
Xi Y; Li J; Zhang P; Bai W; Gao N; Bai W; Zhang Y; Wu Y; Ning Y
Exp Mol Pathol; 2015 Oct; 99(2):297-302. PubMed ID: 26231295
[TBL] [Abstract][Full Text] [Related]
12. Constitutive phosphorylation mutation in Fas-associated death domain (FADD) results in early cell cycle defects.
Osborn SL; Sohn SJ; Winoto A
J Biol Chem; 2007 Aug; 282(31):22786-92. PubMed ID: 17553783
[TBL] [Abstract][Full Text] [Related]
13. The Classical Apoptotic Adaptor FADD Regulates Glycolytic Capacity in Acute Lymphoblastic Leukemia.
Zhou W; Lai Y; Zhu J; Xu X; Yu W; Du Z; Wu L; Zhang X; Hua Z
Int J Biol Sci; 2022; 18(8):3137-3155. PubMed ID: 35637951
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation status of Fas-associated death domain-containing protein regulates telomerase activity and strongly correlates with prostate cancer outcomes.
Matsumura Y; Shimada K; Tanaka N; Fujimoto K; Hirao Y; Konishi N
Pathobiology; 2009; 76(6):293-302. PubMed ID: 19955841
[TBL] [Abstract][Full Text] [Related]
15. Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia.
Verlekar D; Wei SJ; Cho H; Yang S; Kang MH
Cell Death Dis; 2018 Sep; 9(9):925. PubMed ID: 30206207
[TBL] [Abstract][Full Text] [Related]
16. Cooperative phosphorylation of FADD by Aur-A and Plk1 in response to taxol triggers both apoptotic and necrotic cell death.
Jang MS; Lee SJ; Kang NS; Kim E
Cancer Res; 2011 Dec; 71(23):7207-15. PubMed ID: 21978935
[TBL] [Abstract][Full Text] [Related]
17. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.
Tourneur L; Delluc S; Lévy V; Valensi F; Radford-Weiss I; Legrand O; Vargaftig J; Boix C; Macintyre EA; Varet B; Chiocchia G; Buzyn A
Cancer Res; 2004 Nov; 64(21):8101-8. PubMed ID: 15520222
[TBL] [Abstract][Full Text] [Related]
18. RNA interference-mediated silencing of NANOG leads to reduced proliferation and self-renewal, cell cycle arrest and apoptosis in T-cell acute lymphoblastic leukemia cells via the p53 signaling pathway.
Cao J; Li L; Chen C; Lv C; Meng F; Zeng L; Li Z; Wu Q; Zhao K; Pan B; Cheng H; Chen W; Xu K
Leuk Res; 2013 Sep; 37(9):1170-7. PubMed ID: 23683786
[TBL] [Abstract][Full Text] [Related]
19. [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
Pan Y; Li GD; Liu WP; Zhang WY; Tang Y; Li FY
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):810-5. PubMed ID: 20193455
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas.
Chen G; Bhojani MS; Heaford AC; Chang DC; Laxman B; Thomas DG; Griffin LB; Yu J; Coppola JM; Giordano TJ; Lin L; Adams D; Orringer MB; Ross BD; Beer DG; Rehemtulla A
Proc Natl Acad Sci U S A; 2005 Aug; 102(35):12507-12. PubMed ID: 16109772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
